![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, November 03, 2022 6:10:57 PM
IMT505 Rabies ?
(1) Infectious
Illnesses COVID
Vaccine with IMT504 Adjuvant COVID
19 in Kidney Failure Sufferers ?
(2) Oncology CUBT906-
CD56 Monoclonal Antibody ADC Glioblastoma ?
(2)
Degenerative
Eye
Illness
Metformin
Reformulation Age-Associated
Macular Degeneration ?
(1)
(1)Every
of those therapeutics have undergone sure toxicology and pharmacokinetics animal research.
Please see additional description in “Product Growth” under for an additional description
of the event of every indicated therapeutic.(2)Every
of those therapeutics haven’t undergone pre-clinical improvement. Please see additional description
in “Product Growth” under for an additional description of the event of
every indicated therapeutic.
Recent CUBT News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/06/2024 09:31:41 PM
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM